Ayala Pharmaceuticals Inc (ADXS)

[gbrown6332]

KB did a decent job. Obviously time constrained to cover as much ground as possible. Things I noted....

Clear the effort to get an early peak at AXAL data is intended to entice a partner who would assume ongoing trial costs. Referred to AXAL as a stage III asset.

First HOT patient to be dosed in the next few weeks.

Referenced canine osteosarcoma construct as commercially available via an unnamed partner.

Key data readouts during the first half of ‘19 would appear to have make or break implications.

Obviously got hit with a couple of tough financial status questions at the end. Mentioned the efforts to reduce cash burn. Also indicated lots of small biotechs are trading at cash or lower and suggested ADXS was painted with a broad brush across the sector that was prompted by select trial failures by other small immunotherapy companies.

I’m sure others picked up on more info in the quick overview than I did.

G.B.